CD80 and neoplasm: Miao et al. found that tumor-initiating stem cells can selectively acquire CD80 by the cSCC mouse model using scRNA-seq, which directly dampen the cytotoxic T cell activity, implicating the vital role of tumor-initiating stem cells in activating the immune checkpoint therapy [13].